GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (FRA:8V8) » Definitions » Equity-to-Asset

Genetic Analysis AS (FRA:8V8) Equity-to-Asset : 0.60 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Genetic Analysis AS's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €2.28 Mil. Genetic Analysis AS's Total Assets for the quarter that ended in Mar. 2024 was €3.83 Mil. Therefore, Genetic Analysis AS's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.60.

The historical rank and industry rank for Genetic Analysis AS's Equity-to-Asset or its related term are showing as below:

FRA:8V8' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6   Med: 0.74   Max: 0.86
Current: 0.6

During the past 5 years, the highest Equity to Asset Ratio of Genetic Analysis AS was 0.86. The lowest was 0.60. And the median was 0.74.

FRA:8V8's Equity-to-Asset is ranked better than
51.5% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59 vs FRA:8V8: 0.60

Genetic Analysis AS Equity-to-Asset Historical Data

The historical data trend for Genetic Analysis AS's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS Equity-to-Asset Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.74 0.84 0.86 0.69 0.60

Genetic Analysis AS Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.61 0.64 0.60 0.60

Competitive Comparison of Genetic Analysis AS's Equity-to-Asset

For the Diagnostics & Research subindustry, Genetic Analysis AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's Equity-to-Asset falls into.



Genetic Analysis AS Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Genetic Analysis AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.781/4.65
=0.60

Genetic Analysis AS's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=2.281/3.829
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Analysis AS  (FRA:8V8) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Genetic Analysis AS Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Analysis AS (FRA:8V8) Business Description

Traded in Other Exchanges
Address
Kabelgata 8, Oslo, NOR, 0580
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (FRA:8V8) Headlines

No Headlines